A recent study reveals that individuals who discontinue blockbuster slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise regimens.
Findings released in a major health publication shows that while obese individuals often shed substantial amounts of their body weight while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing such treatments should be aware of the danger of quick rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass in about a year and a half.
Weighing Approaches
The analysis, which reviewed dozens of studies involving thousands of participants, contrasted the results of these new drugs with conventional dieting.
The team point out that people who lose weight through diet and exercise usually experience a slower creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Regain
Doctors propose the mode of action of the injections explains the accelerated regain.
These medications mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating far more likely."
A Chronic Disease?
Health authorities recommend the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals argue that, due to the high risk of relapse, the treatment might need to be long-term.
This view is echoed by drug manufacturers, who say that the findings "highlight the chronic nature of excess weight," akin to managing diseases like high blood pressure.
Patient Testimonies
People who have discontinued the medication explain a sudden return of hunger.
"It was like something that goes on and you become ravenous," described one woman.
This challenge is worsened if individuals have not developed lasting lifestyle or habit modifications during therapy.
Widespread Use
Survey data show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest continuing to grow.
- Adoption is higher among females compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Finally, clinicians stress that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent fix and lasting health benefits likely depends on ongoing behavioural changes.
